Sei Investments Co. Purchases 108,821 Shares of Edwards Lifesciences Co. (NYSE:EW)

Sei Investments Co. increased its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 45.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 348,444 shares of the medical research company’s stock after purchasing an additional 108,821 shares during the period. Sei Investments Co. owned 0.06% of Edwards Lifesciences worth $25,795,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of EW. Millstone Evans Group LLC purchased a new stake in Edwards Lifesciences during the 4th quarter valued at approximately $29,000. FSA Wealth Management LLC bought a new position in shares of Edwards Lifesciences during the third quarter worth $30,000. Migdal Insurance & Financial Holdings Ltd. purchased a new position in Edwards Lifesciences during the fourth quarter valued at $30,000. Roble Belko & Company Inc bought a new stake in Edwards Lifesciences in the 4th quarter valued at $46,000. Finally, Catalyst Capital Advisors LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth $54,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Down 0.2 %

Shares of NYSE EW opened at $71.12 on Thursday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The firm has a market capitalization of $41.81 billion, a price-to-earnings ratio of 10.20, a PEG ratio of 4.82 and a beta of 1.12. The stock has a 50 day moving average price of $71.45 and a 200 day moving average price of $70.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the stock in a transaction on Friday, February 14th. The stock was sold at an average price of $76.42, for a total transaction of $438,574.38. Following the sale, the director now owns 60,372 shares of the company’s stock, valued at approximately $4,613,628.24. This trade represents a 8.68 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the transaction, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 62,553 shares of company stock valued at $4,513,064. Company insiders own 1.29% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on EW. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Morgan Stanley upped their price target on shares of Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Wolfe Research cut shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research note on Wednesday, February 12th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price target for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Barclays boosted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 13th. One analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $79.95.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.